Urinary Tract Infections Therapeutics Market Size by Drug, Indications, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2032
Overview
Global Urinary Tract Infections Therapeutics Market size was valued at US$ 9.63 Bn in 2022 and the total revenue is expected to grow at 2.77 % through 2026 to 2032, reaching nearly US$11.66 Bn.
Urinary Tract Infections Therapeutics Market Overview:
In most people, a urinary tract infection (UTI) is one of the most common health problems. As women experience health issues such as menopause, pregnancy, and some birth control side effects, UTI is more common in women than in males. On a global scale, however, the urinary tract infection treatment market is hampered by people's apprehension about consulting doctors and healthcare providers for an accurate diagnosis. In hospitalized patients suffering from complex urinary tract infections, ongoing research and development activities in the urinary tract infection treatment market highlight the predictive features of multidrug-resistant gram-negative bacteria (cUTI).
To know about the Research Methodology :- Request Free Sample Report
Market Dynamics:
As per a study published in Advances in Urology in 2025, kidney stone disease is a growing urological health problem that affects roughly 15% of the world's population. It affects people of all ages, but it affects males more than women between the ages of 20 and 49. Furthermore, roughly 7% of women and 13% of men will acquire a kidney stone during their lives.
As a result, as the pervasiveness of diabetes and kidney stones upsurges, the number of cases of urinary tract infection (UTI) rises, increasing medicine demand and driving the global urinary tract infection therapeutics market. In addition, the market for urinary tract infection therapies is predicted to rise due to the introduction of more effective combination medications and the growing geriatric population.
According to the Center for Education and Research on Therapeutics, about 2 million adverse drug reactions (ADRs) are recorded each year, resulting in over 100,000 deaths and as per the FDA, over 350,000 adverse drug reactions (ADRs) occur in nursing homes alone in the United States each year. With an increase in the number of incidences of adverse drug reactions (ADRs) being recorded globally, there is a greater public awareness of the importance of medication adoption, which is a major restraint for the urinary tract infection treatments market.
In addition, in impoverished nations, there is a lack of awareness regarding the prevalence of UTIs, which is limiting market growth in the forecast timeframe.
Urinary Tract Infections Therapeutics Market Segment Analysis:
The Quinolones segment is dominating the Drug segment of the Global Urinary Tract Infections Therapeutics Market:
Quinolones segment is estimated to boost the global urinary tract infection therapeutics market expansion in the projected time frame. The introduction of numerous mutant bacterial strains around the world has increased the prevalence of infectious diseases. Other factors include the rising prevalence of multi-drug-resistant bacteria, which raises healthcare concerns while also providing sufficient growth prospects for pharmaceutical companies. Quinolones may be able to partially replace other medication therapy due to their significant advantages over other antibacterial medicines. Good oral absorption, quicker tissue penetration, lesser side effects, easy once- or twice-daily dose, and broad-spectrum effectiveness against various pathogenic bacterial strains are just a few of the advantages. Some of the most used quinolones are norfloxacine, ciprofloxacine, enoxacine, moxifloxacin, gatifloxacine, levofloxacine, and trovafloxacine.
The Complicated UTIs segment is considered to supplement the growth of the Global Urinary Tract Infections Therapeutics Market.
The complicated UTIs segment is projected to dominate the market growth of the global urinary tract infection therapeutics market due to the overall rise in drug-resistant bacteria and overuse of antibiotics. Quinolones are prescribed by the great majority of doctors to treat complex UTI situations. Cephalosporin is the second-most-prescribed antibiotic for complex UTIs. Kidney stones are a prevalent illness, as per the American Academy of Family Physicians (AAFP), with an annual incidence of eight cases per 1,000 persons. However, around 13% of men and 7% of women may suffer from kidney stones during their lifetime, and the total incidence of urinary retention in the United States is 4.5 to 6.8 per 1,000 males per year. Overall, the prevalence of complicated UTI is expected to climb over the projected period, owing to rising bacterial resistance in UTI patients and a higher recurrence rate.
Regional Insights:
North America is estimated to grow with the highest CAGR in the forecast timeframe. The factors affecting the growth of the market are an increase in innovations related to diagnostic methodologies used for UTI. During a regular checkup for a urinary tract infection, a woman was found to be infected with E. coli that was resistant to the last-resort drug, Colistin. The finding of Colistin-resistant bacteria was regarded as a significant problem. In addition, the CDC produced guidelines for the prevention of catheter-associated UTIs and other types of healthcare-associated infections in the United States in conjunction with other organizations. Major countries of North America are US, Canada, and Mexico.
The objective of the report is to present a comprehensive analysis of the Global Urinary Tract Infections Therapeutics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the Global Urinary Tract Infections Therapeutics Market dynamics, structure by analyzing the market segments and project the Global market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Global market make the report investor’s guide.
Urinary Tract Infections Therapeutics Market Scope: Inquire before buying
| Global Urinary Tract Infections Therapeutics Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 9.63 USD Billion |
| Forecast Period 2026-2032 CAGR: | 2.77% | Market Size in 2032: | 11.66 USD Billion |
| Segments Covered: | by Drug | Quinolones Penicillin and Combinations Cephalosporin Azoles and Amphotericin B Nitrofurans Other Drugs |
|
| by Indications | Complicated UTI Uncomplicated UTI Other Indications |
||
Urinary Tract Infections Therapeutics Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Urinary Tract Infections Therapeutics Market, Key Players are:
- Pfizer Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca plc
- Sanofi S.A.
- Hoffmann-La Roche AG
- Eli Lilly and Company
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Allergan plc
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Mylan N.V.
- Astellas Pharma Inc.
- Shionogi & Co., Ltd.
- Reddy’s Laboratories Ltd.
- Alkem Laboratories Ltd.
- Bausch Health Companies Inc.
- Paratek Pharmaceuticals, Inc.
- Melinta Therapeutics, Inc.
- MerLion Pharmaceuticals
FAQs:
1. What is the global Urinary Tract Infections Therapeutics market value in 2025?
Ans: Global market value in 2025 was estimated as USD 9.63 Billion USD.
2. What is the global Urinary Tract Infections Therapeutics market growth?
Ans: The global market is anticipated to grow with a CAGR of 2.77% in the forecast period and is likely to reach USD 11.66 Billion by the end of 2032.
3. Which Drug segment is expected to dominate the global Urinary Tract Infections Therapeutics market during the forecast period?
Ans: The Complicated UTI segment is projected to dominate the market growth of the global urinary tract infection therapeutics market due to the overall rise in drug-resistant bacteria and overuse of antibiotics.
4. Who are the key players in the Urinary Tract Infections Therapeutics market?
Ans: Some key players operating in the market include Allergan, Bayer AG, Pfizer, Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Lupin Ltd., Merck & Co., Inc (Merck Sharp & Dohme Corp), Dr. Reddy’s Laboratories Ltd., Almirall, S.A., Cipla, Shionogi and Co., Ltd, Abbott Laboratories, AbbVie Inc., Boehringer Ingelheim International GmbH.
5. What is the key driving factor for the growth of the global Urinary Tract Infections Therapeutics market?
Ans: Key factors that are driving the market growth include the pervasiveness of diabetes and kidney stones upsurges, the number of cases of urinary tract infection (UTI) rises, increasing medicine demand, and driving the global urinary tract infection therapeutics market.